Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01617148
Recruitment Status : Unknown
Verified March 2015 by The Cleveland Clinic.
Recruitment status was:  Active, not recruiting
First Posted : June 12, 2012
Last Update Posted : March 13, 2015
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
The Cleveland Clinic

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : June 2016
  Estimated Study Completion Date : June 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 12, 2017
March 1, 2017
2 March 7, 2017
April 17, 2017
3 April 18, 2017
May 26, 2017
4 January 24, 2018
February 22, 2018
5 February 26, 2018
March 26, 2018
6 March 27, 2018
April 24, 2018